12,583 Shares of United Therapeutics Corporation $UTHR Acquired by Hohimer Wealth Management LLC

Hohimer Wealth Management LLC bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 12,583 shares of the biotechnology company’s stock, valued at approximately $6,819,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. University of Texas Texas AM Investment Management Co. grew its holdings in United Therapeutics by 53.1% during the 3rd quarter. University of Texas Texas AM Investment Management Co. now owns 14,282 shares of the biotechnology company’s stock valued at $7,739,000 after purchasing an additional 4,954 shares in the last quarter. Candriam S.C.A. lifted its holdings in United Therapeutics by 2.7% in the 3rd quarter. Candriam S.C.A. now owns 55,109 shares of the biotechnology company’s stock worth $29,972,000 after buying an additional 1,425 shares in the last quarter. Ethic Inc. lifted its holdings in United Therapeutics by 60.0% in the 3rd quarter. Ethic Inc. now owns 2,463 shares of the biotechnology company’s stock worth $1,335,000 after buying an additional 924 shares in the last quarter. StoneX Group Inc. acquired a new position in United Therapeutics in the 3rd quarter worth $400,000. Finally, Parallel Advisors LLC boosted its position in United Therapeutics by 2.1% in the 3rd quarter. Parallel Advisors LLC now owns 1,154 shares of the biotechnology company’s stock valued at $625,000 after buying an additional 24 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Price Performance

UTHR opened at $562.02 on Monday. The stock has a market capitalization of $23.94 billion, a PE ratio of 21.21, a P/E/G ratio of 3.78 and a beta of 0.49. The firm’s fifty day moving average price is $533.99 and its 200 day moving average price is $533.42. United Therapeutics Corporation has a 12-month low of $444.04 and a 12-month high of $614.23.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). The company had revenue of $832.50 million for the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The company’s revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $7.16 earnings per share. On average, equities research analysts forecast that United Therapeutics Corporation will post 24.77 earnings per share for the current fiscal year.

United Therapeutics declared that its board has approved a share repurchase program on Thursday, October 22nd that permits the company to buy back $2 billion in outstanding shares. This buyback authorization permits the biotechnology company to buy up to 8.3% of its stock through open market purchases. Share buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts raised their price targets and kept bullish ratings. BTIG maintained a Buy rating with a $768 target, citing Tyvaso momentum; Royal Bank of Canada raised its target to $725 and TD Cowen to $700. BTIG analyst outlook
• Positive Sentiment: Third-quarter revenue increased 4.1% year over year to $832.5 million, exceeding analyst expectations of about $781 million. The company also has a $2 billion share-repurchase authorization, which could support demand for its shares.
• Negative Sentiment: Quarterly EPS of $5.71 missed the $6.01 consensus and was below $7.16 a year earlier. The earnings shortfall and year-over-year decline in EPS could offset the revenue beat.
• Negative Sentiment: CEO Martine Rothblatt reported multiple share sales, while EVP Paul Mahon sold 8,300 shares. Insider sales can unsettle investors, although both executives retained substantial holdings after their transactions. CEO sale filing EVP sale filing

Insider Activity

In other news, CEO Martine A. Rothblatt sold 1,960 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $597.76, for a total transaction of $1,171,609.60. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $193,939,047.68. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $598.67, for a total value of $4,968,961.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $27,043,121.24. This trade represents a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 401,528 shares of company stock valued at $213,440,124 in the last three months. Insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of several recent analyst reports. TD Cowen raised their target price on United Therapeutics from $675.00 to $700.00 and gave the company a “buy” rating in a research note on Thursday. Leerink Partners lifted their target price on United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research report on Monday, October 19th. Royal Bank Of Canada boosted their price target on United Therapeutics from $697.00 to $725.00 and gave the stock an “outperform” rating in a research note on Thursday. UBS Group set a $725.00 price target on United Therapeutics in a report on Monday, October 19th. Finally, Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $676.40.

United Therapeutics Profile

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma.

Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.